Article Text

Download PDFPDF

Adherence to medication in patients with rheumatic diseases during COVID-19 pandemic
  1. Alireza Khabbazi,
  2. Hadiseh Kavandi,
  3. Roghayeh Paribanaem,
  4. Raha Khabbazi,
  5. Aida Malek Mahdavi
  1. Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
  1. Correspondence to Dr Aida Malek Mahdavi, Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz 5166614756, Iran; aidamalek{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

With great interest, we read the Pineda-Sic et al’s report on treatment adherence behaviours in rheumatic diseases during COVID-19 pandemic in Latin America.1 They reported that 15.1% of patients with rheumatic disease suspend their medications during COVID-19 crisis.1 Lack of availability (48%) and fear of the immunosuppressive effect of medications (25%) were the most common reasons. To address medication non-adherence in our population, we conducted a study about medication adherence in patients with rheumatic diseases in the East Azarbaijan province, which is one of the provinces of Iran with a high prevalence of COVID-19. The study was conducted in accordance with the Helsinki humanity research declaration (2008). For a period of 2 weeks from 10 to 24 July 2020, information about adherence to medication behaviours of patients after COVID-19 outbreak was obtained by telephone interview in patients with various rheumatic diseases treated with non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, glucocorticoids, synthetic disease-modifying antirheumatic drugs (DMARDs) and biologic DMARDs (bDMARDs). Patients under the age of 16, patients on remission who did not take medication, patients who refused to answer the questions and patients who did not respond to three phone calls were excluded. We defined non-adherence as ≥20% change in the dose or frequency of the mentioned medications.2

After a telephone interview with 1324 patients with various rheumatic diseases, 591 females and 267 males with a mean age of 48.8±13.4 and median (IQR) disease duration of 5 (2, 10) years were enrolled in this study (table 1). Non-adherence was observed in 56 (6.5%) patients after the COVID-19 outbreak. Thirty-nine (6.6%) females and 17 (6.4%) males were non-adherent (p=0.448). Mean age of adherent and non-adherent patients was 49.3±13.6 and 45.3±13.4, respectively (p=0.095). Complete discontinuation of medications was the most common pattern of non-adherence (table 1). Fear of the immunosuppressive effects of medications was the most common reason for medication non-adherence (table 1). bDMARDs, NSAIDs and methotrexate were the medications that patients had the highest percentage of non-adherence to. Non-adherence in patients with seronegative spondyloarthritis was more common than other groups of diseases. The main reason was the higher rate of treatment with bDMARDs in this group of patients in our clinic. Non-adherence leads to exacerbation of symptoms in 9.6% of patients. COVID-19 was developed in 7 (0.8%) patients.

Table 1

Demographic and non-adherence characteristics of patients with rheumatic diseases (n=858)

The data from this study showed that medication non-adherence was not common within 6 months after the issue of COVID-19 is widely discussed in the media. In agreement with our study, Schmeiser et al reported 10% non-adherence in the patients receiving antirheumatic medications.3 Fragoulis et al reported non-adherence to medications in 14.6% of patients with rheumatic diseases in Greece.4 Lack of resources/shortage of drug (3.8%), symptoms suggestive of COVID-19 (2.6%) and fear of immunosuppressive effects of medications (2.2%) were the main reasons for non-adherence. However, it should be noted that this pandemic may last until the end of the year and possibly longer, and with cross-sectional studies, it is not possible to give a definitive opinion on the overall impact of the COVID-19 on the medication adherence of patients with rheumatic diseases for a longer period of time.

Ethics statements

Patient consent for publication

Ethics approval

The study was approved by the Institutional Review Board and Medical Ethics Committee of Tabriz University of Medical Sciences (Ethics Code: IR.TBZMED.REC.1399.178).


The authors thank all the patients and study site personnel for participating in this study.



  • Contributors Study design: AK, HK, AMM. Data collection: AK, HK, RP, RK, AMM. Data analysis: AK, HK, AMM. Interpretation of findings: AK, HK, AMM. Preparation of manuscript: AK, HK, RK, AMM. All authors read and approved the final manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles